drugset / Trial / NCT00040781

Gefitinib in Treating Children With Refractory Solid Tumors

NCT00040781

Phase 1 Completed 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of gefitinib in treating children who have refractory solid tumors. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth

Timeline

Start
2002-06
Primary completion
2004-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule Oral